OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OKYO OKYO Pharma Limited

Market Closed 07-24 16:00:00 EDT

1.55

+0.07

+4.73%

盘后1.55

+0.00+0.14%

19:48 EDT

High1.55	Low1.45	Vol45.74K
Open1.48	D1 Closing1.48	Amplitude6.76%
Mkt Cap81.34M	Tradable Cap43.46M	Total Shares52.48M
T/O68.59K	T/O Rate0.16%	Tradable Shares28.04M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OKYO","market":"US","secType":"STK","nameCN":"OKYO Pharma Limited","latestPrice":1.55,"timestamp":1784923200000,"preClose":1.48,"halted":0,"volume":45738,"hourTrading":{"tag":"盘后","latestPrice":1.5521,"preClose":1.55,"latestTime":"19:48 EDT","volume":570,"amount":884.4661,"timestamp":1784936905449,"change":0.0021,"changeRate":0.001355,"amplitude":0.001355},"delay":0,"changeRate":0.04729729729729734,"floatShares":28039400,"shares":52479300,"eps":-0.24,"marketStatus":"Market Closed","change":0.07,"latestTime":"07-24 16:00:00 EDT","open":1.48,"high":1.55,"low":1.45,"amount":68593.83660360001,"amplitude":0.067568,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.24,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785139200000},"marketStatusCode":7,"adr":0,"adrRate":65,"listingDate":1652760000000,"exchange":"NASDAQ","adjPreClose":1.48,"preHourTrading":{"tag":"盘前","latestPrice":1.54,"preClose":1.48,"latestTime":"08:55 EDT","volume":44,"amount":67.7499988,"timestamp":1784897752328,"change":0.06,"changeRate":0.040541,"amplitude":0.006757},"postHourTrading":{"tag":"盘后","latestPrice":1.5521,"preClose":1.55,"latestTime":"19:48 EDT","volume":570,"amount":884.4661,"timestamp":1784936905449,"change":0.0021,"changeRate":0.001355,"amplitude":0.001355},"volumeRatio":0.207689869662344},"requestUrl":"/m/hq/s/OKYO","defaultTab":"news","newsList":[{"id":"2653724030","title":"OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653724030","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653724030?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:27","pubTimestamp":1784824036,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has provided an announcement. On July 23, 2026, OKYO Pharma announced that non-executive director Joh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-director-ups-stake-ahead-of-planned-phase-3-neuropathic-corneal-pain-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-director-ups-stake-ahead-of-planned-phase-3-neuropathic-corneal-pain-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AADR","OKYO","BK4139","APIE","DIVL","ARMH","CVY","DINT","SAPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653141724","title":"Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38","url":"https://stock-news.laohu8.com/highlight/detail?id=2653141724","media":"TIPRANKS","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653141724?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:05","pubTimestamp":1784822713,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO)announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASD...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-director-john-brancaccio-acquires-5000-shares-at-1-38-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-director-john-brancaccio-acquires-5000-shares-at-1-38-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653724360","title":"OKYO Pharma Director Brancaccio Raises Stake to 35,201 Shares After $1.48 Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2653724360","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653724360?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:00","pubTimestamp":1784822428,"startTime":"0","endTime":"0","summary":"OKYO Pharma director Brancaccio raises stake to 35,201 shares after $1.48 purchaseOKYO Pharma non-executive director John Brancaccio bought 5,000 ordinary shares on Nasdaq at $ 1.48 each.The purchase ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDLbZjtdS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","BCDF","SG9999014005.SGD","BK4588","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","LU0314104364.USD","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","LU2095319765.USD","OKYO","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653764863","title":"Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share","url":"https://stock-news.laohu8.com/highlight/detail?id=2653764863","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653764863?lang=en_us&edition=fundamental","pubTime":"2026-07-23 00:05","pubTimestamp":1784736313,"startTime":"0","endTime":"0","summary":"OKYO Pharma (OKYO) announced that its Chairman, Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, ha...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-says-chairman-gabriele-cerrone-buys-22500-shares-at-1-45-share-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-says-chairman-gabriele-cerrone-buys-22500-shares-at-1-45-share-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653766927","title":"OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653766927","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653766927?lang=en_us&edition=fundamental","pubTime":"2026-07-22 22:27","pubTimestamp":1784730433,"startTime":"0","endTime":"0","summary":"An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. OKYO Pharma Limited is a clinical-stage biopharmaceutical company fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-executive-boosts-shareholding-ahead-of-planned-phase-3-ncp-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-executive-boosts-shareholding-ahead-of-planned-phase-3-ncp-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AADR","CVY","DINT","ARMH","SAPH","APIE","BK4139","OKYO","DIVL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653664765","title":"OKYO Pharma CDO Jacob Lifts Stake to 112,420 Shares with 3,500-share Buy at $1.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2653664765","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653664765?lang=en_us&edition=fundamental","pubTime":"2026-07-22 22:00","pubTimestamp":1784728819,"startTime":"0","endTime":"0","summary":"OKYO Pharma CDO Jacob lifts stake to 112,420 shares with 3,500-share buy at $1.4OKYO Pharma Chief Development Officer and Director Gary S. Jacob bought 3,500 ordinary shares at $1.4 each.The purchase ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL79lzpj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","NDAQ","BK4588","SG9999014021.USD","BK4139","IE00B3QW5Z07.USD","BK4585","IE00B64PRP62.GBP","BK4112","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","LU2210150020.SGD","BCDF","IE00BGHQF748.EUR","SG9999014005.SGD","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653024769","title":"OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2653024769","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653024769?lang=en_us&edition=fundamental","pubTime":"2026-07-22 22:00","pubTimestamp":1784728800,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, July  22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/22/3331510/0/en/OKYO-Pharma-Announces-Purchase-of-Shares-by-Chief-Development-Officer-and-Director.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653878203","title":"OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2653878203","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653878203?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:30","pubTimestamp":1784640611,"startTime":"0","endTime":"0","summary":"An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On July 21, 2026, OKYO Pharma announced it will present at the H.C. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-present-ophthalmology-pipeline-ahead-of-phase-3-urcosimod-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-present-ophthalmology-pipeline-ahead-of-phase-3-urcosimod-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AADR","BK4139","APIE","CVY","OKYO","SAPH","DIVL","DINT","ARMH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653208954","title":"Okyo Pharma Says Chairman Gabriele Cerrone Boosts Stake to 20.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653208954","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653208954?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:15","pubTimestamp":1784639732,"startTime":"0","endTime":"0","summary":"Okyo Pharma  chairman Gabriele Cerrone has increased his stake in the clinical-stage company to 10.9 million shares, or 20.5% of the company's issued shares, with the purchase of 25,000 ordinary shares at $1.40 per share, the company said Tuesday.The purchase was made through Panetta Partners, an entity in which Cerrone has a beneficial interest, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653270059","title":"OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2653270059","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653270059?lang=en_us&edition=fundamental","pubTime":"2026-07-21 21:00","pubTimestamp":1784638800,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, July  21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/21/3330501/0/en/OKYO-Pharma-to-Present-at-the-H-C-Wainwright-6th-Annual-Ophthalmology-Virtual-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653525271","title":"OKYO Pharma Chairman Raises Stake to 20.51% After Buying 25,000 Shares at $ 1.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2653525271","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653525271?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:00","pubTimestamp":1784631621,"startTime":"0","endTime":"0","summary":"OKYO Pharma chairman raises stake to 20.51% after buying 25,000 shares at $ 1.4OKYO Pharma Chairman Gabriele Cerrone bought 25,000 ordinary shares at $ 1.4 via Panetta Partners.Holding rose to 10,851,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL86vThG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014021.USD","LU2210150020.SGD","BK4585","BCDF","BK4588","SG9999014005.SGD","BK4112","SG9999014013.SGD","IE00BN0W2V16.EUR","OKYO","LU2095319765.USD","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","NDAQ","LU2210149790.SGD","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652180612","title":"OKYO Pharma Files Annual Report and Secures Funding for Phase 3 NEPTUNE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2652180612","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652180612?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:57","pubTimestamp":1784548634,"startTime":"0","endTime":"0","summary":"The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ). On July 20, 2026, OKYO Pharma filed its Annual Report on Form 20...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-files-annual-report-and-secures-funding-for-phase-3-neptune-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-files-annual-report-and-secures-funding-for-phase-3-neptune-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVY","DINT","BK4139","SAPH","AADR","DIVL","OKYO","APIE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652185082","title":"OKYO Pharma Says Cash Position Funds Completion of Neptune Phase 3 Urcosimod Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2652185082","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652185082?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:42","pubTimestamp":1784547723,"startTime":"0","endTime":"0","summary":"OKYO Pharma says cash position funds completion of NEPTUNE Phase 3 urcosimod trialOKYO Pharma filed its annual report for the fiscal year ended March 31, 2026, citing a strengthened cash position to f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL1GKFtn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652729089","title":"OKYO Pharma FY26 Net Loss Widens to $8.95 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2652729089","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652729089?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:06","pubTimestamp":1784545598,"startTime":"0","endTime":"0","summary":"OKYO Pharma FY26 net loss widens to $8.95 millionOKYO Pharma posted a net loss of USD 8.95 million, widening from USD 4.71 million a year earlier.Total operating expenses rose to USD 8.5 million from ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL2Xg3H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652970172","title":"OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2652970172","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652970172?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:00","pubTimestamp":1784545200,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, July  20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/20/3329597/0/en/OKYO-Pharma-Announces-Filing-of-Annual-Report-with-Strengthened-Cash-Position-and-Accelerated-Phase-3-Plans.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651113510","title":"OKYO Pharma is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2651113510","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651113510?lang=en_us&edition=fundamental","pubTime":"2026-07-13 18:20","pubTimestamp":1783938000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings(END) Dow Jones NewswiresJuly 13, 2026 06:20 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649993505","title":"Okyo Pharma receives feedback from FDA Type D meeting on urcosimod pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2649993505","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649993505?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:30","pubTimestamp":1783510242,"startTime":"0","endTime":"0","summary":"Okyo Pharma (OKYO) announced feedback from its FDA Type D meeting, validating the company’s regulatory and clinical path forward for urcosimod and ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/okyo-pharma-receives-feedback-from-fda-type-d-meeting-on-urcosimod-pathway-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/okyo-pharma-receives-feedback-from-fda-type-d-meeting-on-urcosimod-pathway-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4588","OKYO","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649296008","title":"OKYO Pharma Reports Positive Feedback from FDA Type D Meeting and Accelerates Urcosimod into Global Phase 3 Pivotal Trial for Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2649296008","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649296008?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:00","pubTimestamp":1783508400,"startTime":"0","endTime":"0","summary":"FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway further strengthens the Company's clinical development program for urcosimodCompany unveils NEPTUNE ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/08/3323947/0/en/OKYO-Pharma-Reports-Positive-Feedback-from-FDA-Type-D-Meeting-and-Accelerates-Urcosimod-into-Global-Phase-3-Pivotal-Trial-for-Neuropathic-Corneal-Pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","OKYO","BK4139","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649648984","title":"OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2649648984","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649648984?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:00","pubTimestamp":1783422000,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, July  07, 2026  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neurop","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323040/0/en/OKYO-Pharma-to-Participate-in-a-Fireside-Chat-at-Piper-Sandler-2026-Virtual-Ophthalmology-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OKYO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644729719","title":"OKYO Pharma files Form 3 initial beneficial ownership for CMO Flavio Mantelli","url":"https://stock-news.laohu8.com/highlight/detail?id=2644729719","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644729719?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:15","pubTimestamp":1781727354,"startTime":"0","endTime":"0","summary":"OKYO Pharma Chief Medical Officer Flavio Mantelli reported direct holdings of options for 750,000 common shares at an exercise price of $1.96.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL27xFmf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.okyopharma.com","stockEarnings":[{"period":"1week","weight":0.0839},{"period":"1month","weight":0},{"period":"3month","weight":-0.0373},{"period":"6month","weight":-0.3018},{"period":"1year","weight":-0.4384},{"period":"ytd","weight":-0.2512}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0078},{"period":"3month","weight":0.035},{"period":"6month","weight":0.0721},{"period":"1year","weight":0.1647},{"period":"ytd","weight":0.0836}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.016922},{"month":2,"riseRate":0.25,"avgChangeRate":-0.048425},{"month":3,"riseRate":0.5,"avgChangeRate":-0.0442},{"month":4,"riseRate":0.5,"avgChangeRate":-0.006578},{"month":5,"riseRate":0.75,"avgChangeRate":0.124495},{"month":6,"riseRate":0.4,"avgChangeRate":-0.035766},{"month":7,"riseRate":1,"avgChangeRate":0.17382},{"month":8,"riseRate":0.5,"avgChangeRate":0.008913},{"month":9,"riseRate":0.25,"avgChangeRate":-0.093671},{"month":10,"riseRate":0.5,"avgChangeRate":0.07182},{"month":11,"riseRate":0,"avgChangeRate":-0.142327},{"month":12,"riseRate":0.75,"avgChangeRate":0.059341}],"exchange":"NASDAQ","name":"OKYO Pharma Limited","nameEN":"OKYO Pharma Limited","securityTypeName":"DR","adrRate":"1:65"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OKYO Pharma Limited,OKYO,OKYO Pharma Limited股票,OKYO Pharma Limited股票老虎,OKYO Pharma Limited股票老虎国际,OKYO Pharma Limited行情,OKYO Pharma Limited股票行情,OKYO Pharma Limited股价,OKYO Pharma Limited股市,OKYO Pharma Limited股票价格,OKYO Pharma Limited股票交易,OKYO Pharma Limited股票购买,OKYO Pharma Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction